FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/11/077199 [Registered on: 21/11/2024] Trial Registered Prospectively
Last Modified On: 20/11/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Unani 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Efficacy of a Unani Formulation in the Management of Diabetes Mellitus 
Scientific Title of Study   A Clinical Study to Evaluate the Efficacy and Safety of a Unani Formulation in the Management of Ziabetus Shakari (Diabetes Mellitus): A Randomized, Active Controlled, Parallel Group Clinical Trial 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Saba Khan 
Designation  Pg Scholar 
Affiliation  State Takmeel ut Tib College and Hospital Lucknow 
Address  Department of Moalajat State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabaad Tiraha Lucknow India 226002

Lucknow
UTTAR PRADESH
226002
India 
Phone  7217813082  
Fax    
Email  khansabajamia2@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Abdul Qadir 
Designation  Associate Professor 
Affiliation  State Takmeel ut Tib College and Hospital Lucknow 
Address  Department of Moalajat State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow India 226002

Lucknow
UTTAR PRADESH
226002
India 
Phone  9415757169  
Fax    
Email  aq.ayaz5775@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Abdul Qadir 
Designation  Associate Professor 
Affiliation  State Takmeel ut Tib College and Hospital Lucknow 
Address  Department of Moalajat State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow India 226002

Lucknow
UTTAR PRADESH
226002
India 
Phone  9415757169  
Fax    
Email  aq.ayaz5775@gmail.com  
 
Source of Monetary or Material Support  
State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabad Tiraha Lucknow India 226002 
 
Primary Sponsor  
Name  Dr Saba Khan 
Address  Department of Moalajat State Takmeel ut Tib College and Hospital Near Ramabai Raily Sthal Aurangabaad Tiraha Lucknow India 226002 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Saba Khan  State Takmeel ut Tib College and Hospital   OPD Department of Moalajat Near Ramabai Raily Sthal Bijnor Road Aurangabad Tiraha Lucknow 226002
Lucknow
UTTAR PRADESH 
7217813082

khansabajamia2@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical Committee for Biomedical Research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications, (2) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Tab Metformin  Tab Metformin Dosage Form: Tablets Dose: 500mg Frequency: Twice a Day half hour before meals Route of Administration: Orally Duration: 60 Days 
Intervention  Unani Polyherbal Formulation   Unani Polyherbal Formulation Dosage Form: Safuf (Powder) Dose: 6gm Frequency: Twice a Day half hour before meals Route of Administration: Orally Duration: 60 Days 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Patients age group 18 to 60 years old of any gender.
Fasting Plasma Glucose levels between 126mg/dl and 150 mg/dl or Postparandial Plasma Glucose levels ranging from 200 mg/dl to 250 mg/dl 2 hour after ingestion of 75mg of glucose in 300ml of water or HbA1C levels ranging 6.5% to 10%.
Presence of symptoms and signs of diabetes mellitus type2. 
 
ExclusionCriteria 
Details  Patients having any deliberating systemic disease.
Patients on insulin therapy and suffering from diabetes mellitus type-1.
Patients with complications of Diabetes mellitus type2
Patients suffering from thyroid function disorders.
Pregnant and lactating women.
Known case of immunocompromised states (HIC, AIDS etc) or malignancies. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1 Fasting and PP glucose level
2 HBA1c level
3 Improvement in symptoms and signs on VAS Scale (0-10) 
Baseline
2 Weeks
4 Weeks
6 Weeks
8 Weeks 
 
Secondary Outcome  
Outcome  TimePoints 
1 Haemogram
2 Lft
3 Kft
4 Lipid Profile
5 Urine RM 
Baseline
2 Weeks
4 Weeks
6 Weeks
8 Weeks 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "60"
Final Enrollment numbers achieved (India)="60" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   01/12/2024 
Date of Study Completion (India) 01/06/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Dhayabitus Shakari (Diabetes mellitus) is a clinical syndrome of multiple etiologies characterized by an increase in plasma blood glucose (hyperglycemia) with disturbances of carbohydrate, fat, and protein metabolism. There are two main types of diabetes mellitus: type 1 and type 2. Type 1 diabetes is generally considered to result from autoimmune destruction of insulin-producing cells (β cells) in the pancreas, leading to marked insulin deficiency, whereas type 2 diabetes is characterized by reduced sensitivity to the action of insulin and an inability to produce sufficient insulin to overcome ‘insulin resistance’. Millions of individuals are affected by diabetes mellitus type II , which is the most common and rapidly progressing serious non-communicable disease in the world. Diabetes that has not been properly diagnosed results   in   various complications. Chronic hyperglycemia is responsible for diabetes-specific microvascular complications affecting the eyes (retinopathy), kidneys (nephropathy), and feet (neuropathy)1 and macrovascular complications include cardiovascular, cerebrovascular, and peripheral vascular disease.


The prevalence of diabetes has reached epidemic levels. Diabetes mellitus is rapidly becoming one of the most common non-communicable diseases. WHO reports diabetes mellitus as the ninth leading cause of death globally, accounting for 74% of global deaths in 2019. The International Diabetes Federation (IDF) reports that diabetes kills one person every seven seconds and kills about 3.2 million people every year worldwide. In India, there were 31.7 million individuals with diabetes overall in 2000, and 79.4 million are project to have the disease by 2030. Between 2000 and 2030, it is expected that the number of urban diabetics in emerging nations will double. Diabetes is predicted to kill 592 million people by 2035.


In the Unani system of medicine, physicians used various names for Dhayabitus, including Moattasha, Atsha, Zalaqul Kulliya, Dolab, Dawwarah, Barkar, Barkarya, and Qaramees. The various facts of diabetes mellitus have been well documented and addressed in unani classical Unani texts. Dhayabitus is a kidney disease, and it has been described as the patient passing the urine promptly just after taking water.  Ibne Sina termed it Zalaqul Kulliya. The etiopathogenesis of Dhayabitus Shakari in unani literature is based on Sue mizaj gurda (derangement in temperament), Zauf-e-kulliya (weakness of kidney) and Structural deviation (Ittasa-e- gurda). Many antidiabetic drugs found in Unani treasures are of natural origin. They are not only effective and potent in controlling glucose levels but also equally safe and less harmful than their modern counterparts. Various single (mufrad) and compound (murakkab) antidiabetic drugs like Maghze jamun, Methi, Satte gilo, Gulnaar, Tabasheer, Gil-e-armani, Tukhm-e- konch and Qurs-e- Kafoor, Qurs-e- Tabasheer, Qurs-e- Dhayabitus, Qurs-e-Gulnaar etc. are mentioned in unani literature.


Keeping the above facts in mind, the present study entitled "A Clinical Study to Evaluate the Efficacy        and Safety of a Unani Formulation in the management of Dhayabitus Shakari (Diabetes Mellitus): A Randomized, Active Controlled, Parallel Group Clinical Trial” has been          designed. A polyherbal unani formulation in powdered form containing Tabasheer (Bambusa arundinacea), Gulnaar (Punica granatum), Gile Armini (Armenia Bole), Tukhm Khurfa (Portulaca oleracea) and Tukhm Kaahu (Lactuca sativa) is selected to evaluate its efficacy and safety in the management of Dhayabitus Shakari Qism Sani (Diabetes Mellitus type 2).


 
Close